This editorial has been written at the request of the National Eczema Association for Science and Education (NEASE), San Rafael, Calif. The purpose is to provide an objective, independent view of the evidence surrounding the effectiveness and possible adverse effects of topical calcineurin inhibitors (TCIs) in response to the recent US Food and Drug Administration (FDA) concerns.1 This editorial is meant for patients with atopic dermatitis (AD) and their health care providers.
Qureshi AA, Fischer MA. Topical Calcineurin Inhibitors for Atopic DermatitisBalancing Clinical Benefit and Possible Risks. Arch Dermatol. 2006;142(5):633-637. doi:10.1001/archderm.142.5.633